MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaip.2022.11.044

Медицинская библиотека · The journal of allergy and clinical immunology. In practice · 2022

Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.

Brusselle Guy, Quirce Santiago, Papi Alberto, Kuna Piotr, Chipps Bradley E, Hanania Nicola A, Blaiss Michael, Msihid Jérôme, Jacob-Nara Juby A, Deniz Yamo, Rowe Paul J, Gall Rebecca, Ortiz Benjamin, Djandji Michel, Radwan Amr

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Type 2 cytokines IL-4/IL-5/IL-13 play an important role in pathogenesis of type 2 conditions, including asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting signaling. In phase 2b (P2B) (NCT01854047) and phase 3 VENTURE (NCT02528214), dupilumab reduced annualized severe exacerbation rates (AER), improved forced expiratory volume in 1 second (FEV1), and was generally well tolerated in patients with uncontrolled, moderate-to-severe, or oral corticosteroid (OCS)-dependent severe asthma.

OBJECTIVE

The post hoc assessment of dupilumab efficacy versus placebo in P2B and VENTURE in patients stratified by allergic status.

METHODS

Allergic asthma was defined as total serum IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline. AER, prebronchodilator (BD) FEV1, FEV1/forced vital capacity (FVC) ratio, asthma control (5-item Asthma Control Questionnaire), health-related quality of life (HRQoL; Asthma Quality of Life Questionnaire), type 2 biomarkers, specific IgE, and OCS reduction (VENTURE only) were assessed.

RESULTS

In patients with allergic asthma, dupilumab (P2B: pooled 200/300 mg; VENTURE: 300 mg) every 2 weeks versus placebo reduced AER (P2B: -60%, P < .01; VENTURE: -72%, P < .001), and, in P2B, increased pre-BD FEV1 (P < .01) and FEV1/FVC (P < .05). In both studies, dupilumab significantly improved asthma control and HRQoL and reduced most type 2 biomarkers. Dupilumab significantly reduced OCS use in VENTURE. Similar benefits were observed in patients without evidence of allergic asthma.

CONCLUSIONS

Dupilumab significantly reduced AER and improved lung function, asthma control, and HRQoL in patients with or without evidence of allergic asthma.

Для цитирования: Brusselle Guy, Quirce Santiago, Papi Alberto, Kuna Piotr, Chipps Bradley E, Hanania Nicola A, Blaiss Michael, Msihid Jérôme, Jacob-Nara Juby A, Deniz Yamo, Rowe Paul J, Gall Rebecca, Ortiz Benjamin, Djandji Michel, Radwan Amr. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.. The journal of allergy and clinical immunology. In practice. 2022. DOI: 10.1016/j.jaip.2022.11.044.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.